Editors-in-Chief
- Mark Slevin, Manchester Metropolitan University
- Yihai Cao, Karolinska Institute
- Jan Kitajewski, Columbia University Medical Center
Articles
-
Research
Vascular Cell 2012, 4:10 (15 May 2012)The Angiogenic Response is Dependent on Ultrasound Contrast Agent Concentration
-
Review
Vascular Cell 2012, 4:9 (30 April 2012)Unique vascular protective properties of natural products: supplements or future main-line drugs with significant anti-atherosclerotic potential?
-
Research
Vascular Cell 2012, 4:8 (18 April 2012)Angiogenic efficacy of Heparin on chick chorioallantoic membrane
-
Review
Vascular Cell 2012, 4:7 (9 April 2012)Notch signals in the endothelium and cancer "stem-like" cells: opportunities for cancer therapy
-
Correction
Vascular Cell 2012, 4:6 (26 March 2012)Correction: Co-culture of Retinal and Endothelial Cells Results in the Modulation of Genes Critical to Retinal Neovascularization
-
Research
Vascular Cell 2012, 4:5 (20 March 2012)Positron emission tomography detection of human endothelial cell and fibroblast monolayers: effect of pretreament and cell density on 18FDG uptake
-
Research
Vascular Cell 2012, 4:4 (16 March 2012)Pleiotrophin expression and role in physiological angiogenesis in vivo: Potential involvement of nucleolin
- View more articles
From the blog
- 10 December 2011
- Perspectives and opportunities for nanomedicine in the management of atherosclerosis.
- 11 November 2011
- N-CAM Exhibits a Regulatory Function in Pathological Angiogenesis in Oxygen Induced Retinopathy
Aims & scope
Vascular Cell is an open access journal that publishes original research and timely reviews on recent advances in the understanding of the processes responsible for neovascularisation and pathological angiogenesis.
Thematic series
Cell-based therapeutics in cardiovascular medicine: from angiogenesis to large vessel repair
Edited by Todd McAllister
Published: 14 October 2011
The Dll4/Notch pathway as a therapeutic target in tumors
Edited by Jan Kitajewski
Published: 8 August 2011
Angiogenesis and nanomedical interventions
Edited by Mark Slevin
Published: 8 October 2010
Editors' quote
Mark Slevin
"I feel privileged to be working in this exciting field of vascular biology, and to be associated with the journal Vascular Cell as we move towards the point of a critical understanding of mechanisms of blood vessel formation and function. Armed with this information, and coupled with expertise from multidisciplinary fields such as nano-medicine, genetic engineering and tissue imaging, over the next decade, we should be able to introduce effective new clinical therapies targeting the major angiogenic diseases, which include cancer, heart disease and stroke."
Yihai Cao
"Being an expert in vascular biology, I feel extremely privileged and excited to serve the scientific community as one of the Editors-in-Chief of Vascular Cell. Vascular biology is one of the most exciting and fast-expanding areas in biomedical research. It covers almost all areas in medical research and has cross-disciplinary clinical implications for the treatment of most common and lethal human diseases including cancer, cardiovascular disease and metabolic disease. Our goal is to launch Vascular Cell as one of the most authoritative journals in the field of vascular biology by publishing high-quality papers across the entire vascular biology area, with particular emphasis on translational research in this area. Together with Professors Slevin and Kitajewski, I look forward to serving the scientific community by reporting your groundbreaking discoveries in this high-impact journal."
Jan Kitajewski
"Today, there are unprecedented opportunities to utilize model systems to better understand the construction and pathologies of the vasculature, and to translate this knowledge to improve human health. We will strive to develop Vascular Cell as a home for reporting on timely research discoveries that shine a light on the vasculature in health and disease."
Email updates
Receive periodic news and updates relating to this journal.